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The Leishmania isoform of the 90kDa Heat Shock Protein (LsHsp90), a chaperone known to assist the folding 
of more than 200 client proteins, was reported to be generally involved in parasite differentiation from 
promastigote to amastigote possessing a pivotal role during heat-induced cellular stress. Moreover, it was 
demonstrated that an impair of the native functions of LsHsp90 through the action of active-site inhibitors 
can exert a detrimental effect on the natural parasite life-cycle ultimately leading to its death.1,2 
Celastrol (Figure 1) is a natural triterpene exhibiting a plethora of in vitro and in vivo activities. Among them, 
this pentacyclic compound is reported to possess a promising antiproliferative activity thanks to its ability of 
interacting with the chaperone cycle of the human isoform of Hsp90 (hHsp90).3 Moreover, celastrol 
derivatives (e.g. the methyl ester pristimerin, Figure 1) have also exhibited an interesting antiprotozoal 
activity.4,5 
With the aim of building a target-oriented approach to treat Leishmania infections based on the inhibition of 
LsHsp90, we prepared two basic carboxamides celastrol derivatives (SS-1 and SS-2, Figure 1) to enhance its 
leishmanicidal activity and selectivity of action by deducting its unspecific cytotoxicity (measured as IC50 on 
HMEC-1 cell lines). Accordingly, celastrol and the two basic derivatives SS-1 and SS-2 (Figure 1) were in vitro 
tested for their leishmanicidal activity against promastigotes of Leishmania tropica and L. infantum and, in 
parallel, their mechanism of action was investigated as well via ad hoc in vitro experiments using a 
recombinant Hsp90 from L. braziliensis (LbHsp90).6 
 
Figure 1. Structures of celastrol, pristimerin and the basic derivatives SS-1 and SS-2. 
 
In virtue of their pH sensitive basic heads, both SS-1 and SS-2 were found to be more potent (IC50 in the 
nanomolar range) and selective leishmanicidal agents than celastrol itself. Furthermore, we were able to 
demonstrate that SS-1 and SS-2 successfully (in vitro) inhibited the native kinase activity of LbHsp90 
highlighting the key role of the inhibition of this chaperone in their mechanism of action. 
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